A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment
 of postherpetic neuralgia in a dose-ranging manner.
Inclusion Criteria:

 -  Visual Analogue Scale (VAS) of pain is higher than 40 mm.

 -  Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

 Exclusion Criteria:

 -  Malignancy within the past 2 years.

 -  Patients who have undergone neurolytic or neurosurgical therapy for postherpetic
 neuralgia.

 -  Creatinine clearance </= 30 mL/min (estimated from serum creatinine, body weight, age,
 and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).

 -  Patients having other severe pain which may impair the self assessment of the pain due
 to postherpetic neuralgia.

 -  Skin conditions in the affected dermatome that could alter sensation.